Neoplasms, Connective and Soft Tissue  >>  conatumumab (AMG 655)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
conatumumab (AMG 655) / Amgen
NCT00626704: Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Completed
1b/2
134
US, Europe
AMG 655, Conatumumab, Placebo, Doxorubicin
Amgen
Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma, Sarcoma, Soft Tissue Sarcoma
08/09
03/11

Download Options